DDrare: Database of Drug Development for Rare Diseases

Searched query = "Hereditary pancreatitis", "Chronic pancreatitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 98% dehydrated alcohol; A04AD10; ACETYLCYSTEINE; ANTOX; ANTOX (vers) 1.2; ANTOX (vers.)1.2; ASCORBIC ACID; Acetate; Acetyl-L-carnitine; Acetyl-L-carnitine 1000mg 2X per day for 3 months; Acetylcysteine; Alanine; Alcohol; Alpha 1-Antitrypsin; Alpha 1-antitrypsin; Amino acids; Amlodipine; Amlodipine (drug); Analgesics; Antioxidant plus Pregabalin; Antioxidants; Antox version 1.2; Ascorbic acid; Autologous mesenchymal stromal cell; Behavioral: smoking and alcohol assumption; Benzoyl-L-tyrosyl-[1-13C]alanine (Bz-Tyr-Ala); Bupivacaine; Bupivicaine alone; CREON; Calcium; Calcium, Dietary; Carbon; Carbon monoxide; Carnitine; Cholecalciferol; Creon; Creon 10000; Creon 25000; Creon36™; DRONABINOL; Device: Mayo Interactive Breath Hold Monitor; Diagnostic Test: Hemoglobin A1c; Diagnostic Test: Mixed Meal Tolerance Test; Diagnostic Test: Other exploratory blood biomarkers; Diagnostic Test: genetic sequencing; Diazepam; Dronabinol; ERCP with Bupivacaine infusion; EUR-1008 (APT-1008) High Dose; EUR-1008 (APT-1008) Low Dose; EUR-1066-A; EUR-1066-B; EUS procedure with drug injection; Ensure Surgical; Esomeprazole; Etanercept; FLUIMUCIL*20CPR EFF 600MG; Fluimucil; Gabapentin; Gabapentin prescriptions; Gold; Helopanflat Mono®; Hemoglobin; Human Secretin; Human secretin; Hydroxychloroquine; Indomethacin; Intra Plexus Triamcinolone and Bupivicaine Injection; Kreon 25000; L-Carnitine; LANREOTIDE ACETATE; LIPASE; Lannacher; Lanreotide; Liprotamase; Lyrica; Lyrica®; MAGNESIUM ASPARTATE HYDROCHLORIDE; METHIONINE; MONITOR; MS1819; MS1819-SD; Magnesiocard 2.5mmol; Magnesium; Magnesium aspartate; Methionine; Mezym F; Midazolam; Multienzymes (lipase, protease etc.); NI-03; Namisol; Nexium (esomeprazole magnesium); OXYCODONE; OXYCODONE HYDROCHLORIDE; Omeprazole; Other: Carbon monoxide-bubbled mediums; Other: EUS procedure; Other: Laboratory Biomarker Analysis; Other: Low-intensity exercise therapy; Other: No enzyme therapy; Other: Nutrition counseling; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Oxycodone; Oxycodone Depot ”Sandoz”, depot tablets; Oxycodonhydrochlorid ”Lannacher”, depot tablets; Oxynorm; PFD; PL 00512/0150; Pancreatic enzymes; Pancreatin; Pancrelipase; Pancrelipase Delayed Release Capsule; Pancrelipase delayed release capsule; Pancrelipase/Pancreas Powder; Panzytrat; Panzytrat 25.000; Panzytrat 25.000 FIP-E units of Lipase; Pentoxifylline; Perflubutane; Pioglitazone; Pregabalin; Procedure: Celiac Block with triamcinolone and bupivicaine; Procedure: No Celiac Block; Procedure: endoscopic drainage of the main pancreatic duct; Procedure: extracorporeal shock wave lithotripsy; Prolastin; Prolastin-C; Proton pump inhibitor (PPI); REGN475/SAR164877; RG1068 (Synthetic Human Secretin); RVG 13760; Radiation: UV-filtered light.; Radiation: UVB; Recombinant Microbial Lipase SLV339; Recombinant microbial lipase; Reparixin; S-Ketamin; S-ketamin; SA; SA-001; SELENIUM; SLV339; Secretin; Selenium; Simvastatin; Somatuline; Somatuline Autogel 90 mg; Soy bread; Synthetic human secretin; TOCOPHEROL; Tanezumab; Tetrahydro-6,6,9-tri methyl-3-penthyl-6 H-dibenzo[ b,d ]pyran-1-ol; Tetrahydrocannabinol; Thalidomide; Tocopherol; Triamcinolone; Tyr; VIOKASE 16; Viokase 16; Viokase 16 (pancrelipase) + Nexium; Viokase® 16; Vitamin D; Vitamin D 100ug; Vitamin D 10ug; Yarrowia lipolytica lipase; ZENTASE; Zenpep

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01551511 (ClinicalTrials.gov)	October 2012	7/2/2012	?9-THC (Namisol®) in Chronic Pancreatitis Patients Suffering From Persistent Abdominal Pain	?9-THC (Namisol®) in Chronic Pancreatitis Patients Suffering From Persistent Abdominal Pain: a Randomized, Double-blinded, Placebo-controlled, Parallel Design	Pancreatitis, Chronic;Abdominal Pain;Chronic Pain	Drug: Tetrahydrocannabinol;Drug: Placebo	Radboud University	European Union	Completed	18 Years	N/A	Both	29	Phase 2	Netherlands
2	EUCTR2012-000730-19-NL (EUCTR)	23/08/2012	12/03/2012	?9-THC (Namisol®) in Chronic Pancreatitis Patients Suffering From Persistent Abdominal Pain	The analgesic efficacy of ?9-THC (Namisol®) in Chronic Pancreatitis Patients Suffering From Persistent Abdominal Pain: a Randomized, Double-blinded, Placebo-controlled, Parallel Design - Delta-Pain II	Chronic pancreatitis with persistant abdominal pain MedDRA version: 14.1;Level: PT;Classification code 10033649;Term: Pancreatitis chronic;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Body processes [G] - Digestive System and Oral Physiological Phenomena [G10]	Product Name: Namisol Product Code: A04AD10 INN or Proposed INN: DRONABINOL Other descriptive name: Tetrahydro-6,6,9-tri methyl-3-penthyl-6 H-dibenzo[ b,d ]pyran-1-ol	Radboud University Nijmegen Medical Centre	NULL	Not Recruiting			Female: yes Male: yes	68	Phase 2	Netherlands
3	NCT01318369 (ClinicalTrials.gov)	October 2011	9/3/2011	Efficacy Study of ?9-THC to Treat Chronic Abdominal Pain	The Safety, Tolerability, and Analgesic Efficacy of ?9-THC (Namisol®) in Chronic Pancreatitis Patients Suffering From Persistent Abdominal Pain	Cannabinoid;Tetrahydrocannabinol;Chronic Pancreatitis;Abdominal Pain	Drug: Namisol;Drug: Diazepam	Radboud University	NULL	Completed	18 Years	N/A	Both	24	Phase 2	Netherlands
4	EUCTR2011-000647-24-NL (EUCTR)	26/07/2011	12/05/2011	Efficacy study of ?9-THC to treat persistent abdominal pain as a result of chronic pancreas inflammation	The safety, tolerability, and analgesic efficacy of ?9-THC (Namisol®) in chronic pancreatitis patients suffering from persistent abdominal pain - ?9-THC in chronic pain	patients with abdominal pain as a result of chronic pancreatitis MedDRA version: 13.1;Level: PT;Classification code 10033649;Term: Pancreatitis chronic;System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 13.1;Level: LLT;Classification code 10009093;Term: Chronic pancreatitis;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: Namisol Product Code: A04AD10 INN or Proposed INN: DRONABINOL	Radboud University Nijmegen Medical Centre	NULL	Not Recruiting			Female: no Male: yes			Netherlands

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT01551511
(ClinicalTrials.gov)

October 2012

7/2/2012

?9-THC (Namisol®) in Chronic Pancreatitis Patients Suffering From Persistent Abdominal Pain

?9-THC (Namisol®) in Chronic Pancreatitis Patients Suffering From Persistent Abdominal Pain: a Randomized, Double-blinded, Placebo-controlled, Parallel Design

Pancreatitis, Chronic;Abdominal Pain;Chronic Pain

Drug: Tetrahydrocannabinol;Drug: Placebo

Radboud University

European Union

Completed

18 Years

N/A

Both

Phase 2

Netherlands

EUCTR2012-000730-19-NL
(EUCTR)

23/08/2012

12/03/2012

?9-THC (Namisol®) in Chronic Pancreatitis Patients Suffering From Persistent Abdominal Pain

The analgesic efficacy of ?9-THC (Namisol®) in Chronic Pancreatitis Patients Suffering From Persistent Abdominal Pain: a Randomized, Double-blinded, Placebo-controlled, Parallel Design - Delta-Pain II

Chronic pancreatitis with persistant abdominal pain
MedDRA version: 14.1;Level: PT;Classification code 10033649;Term: Pancreatitis chronic;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Body processes [G] - Digestive System and Oral Physiological Phenomena [G10]

Product Name: Namisol
Product Code: A04AD10
INN or Proposed INN: DRONABINOL
Other descriptive name: Tetrahydro-6,6,9-tri methyl-3-penthyl-6 H-dibenzo[ b,d ]pyran-1-ol

Radboud University Nijmegen Medical Centre

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

Netherlands

NCT01318369
(ClinicalTrials.gov)

October 2011

9/3/2011

Efficacy Study of ?9-THC to Treat Chronic Abdominal Pain

The Safety, Tolerability, and Analgesic Efficacy of ?9-THC (Namisol®) in Chronic Pancreatitis Patients Suffering From Persistent Abdominal Pain

Cannabinoid;Tetrahydrocannabinol;Chronic Pancreatitis;Abdominal Pain

Drug: Namisol;Drug: Diazepam

Radboud University

NULL

Completed

18 Years

N/A

Both

Phase 2

Netherlands

EUCTR2011-000647-24-NL
(EUCTR)

26/07/2011

12/05/2011

Efficacy study of ?9-THC to treat persistent abdominal pain as a result of chronic pancreas inflammation

The safety, tolerability, and analgesic efficacy of ?9-THC (Namisol®) in chronic pancreatitis patients suffering from persistent abdominal pain - ?9-THC in chronic pain

patients with abdominal pain as a result of chronic pancreatitis
MedDRA version: 13.1;Level: PT;Classification code 10033649;Term: Pancreatitis chronic;System Organ Class: 10017947 - Gastrointestinal disorders
MedDRA version: 13.1;Level: LLT;Classification code 10009093;Term: Chronic pancreatitis;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]

Product Name: Namisol
Product Code: A04AD10
INN or Proposed INN: DRONABINOL

Radboud University Nijmegen Medical Centre

NULL

Not Recruiting

Female: no
Male: yes

Netherlands